Table 1.
Demographics and mean baseline measures (in session 1) as function of administered dose. Standard deviations are in parentheses. Results of group comparisons using Pearson chi-square (for sex) and ANOVAs (all other variables) are listed under “p value”.
| Placebo (n = 30) | 6 mg (n = 30) | 15 mg (n = 30) | 30 mg (n = 30) | p value | |
|---|---|---|---|---|---|
| Age | 23.0 (2.1) | 22.9 (2.5) | 22.1 (2.1) | 22.3 (2.1) | 0.30 |
| Sex | 16 female | 18 female | 12 female | 15 female | 0.48 |
| Weight | 71 (12) | 75 (17) | 67 (11) | 68 (11) | 0.11 |
| BMI | 23.0 (3.2) | 23.9 (3.7) | 22.7 (2.3) | 22.6 (2.5) | 0.28 |
| BIS/BAS | 5.8 (0.6) | 5.7 (0.6) | 5.9 (0.6) | 6.0 (0.6) | 0.25 |
| BIS-11 | 1.9 (0.3) | 1.8 (0.2) | 1.9 (0.2) | 1.9 (0.2) | 0.21 |
| MWTB | 29.7 (3.2) | 28.6 (4.4) | 27.7 (3.6) | 29.8 (2.6) | 0.07 |
| Digit span | 5.6 (2.2) | 6.3 (2.0) | 6.3 (1.2) | 5.9 (2.1) | 0.41 |